Health
China’s 2nd protein subunit COVID-19 vaccine to enter clinical trials, easy to mass produce – Global Times
China’s COVID-19 protein subunit vaccines have reported encouraging progress as a leading Chinese vaccine producer, Sinopharm, plans to bring its newly developed…
Sinopharm’s COVID-19 vaccine. Photo: VCG
China’s COVID-19 protein subunit vaccines have reported encouraging progress as a leading Chinese vaccine producer, Sinopharm, plans to bring its newly developed recombinant subunit vaccine candidate into clinical trials.
Sinopharm’s vaccine is the second protein subunit vaccine in the country after one developed by China’s Anhui Zhifei Longcom Biopharmaceutical Co, which started late-stage trials in Pakistan upon approval on Sunday.
The protein subunit vaccine…
-
Noosa News23 hours agoCommissioner thanks police officer who threw a speed radar at a car
-
Noosa News22 hours agoNo matter what happens in his Origin debut, history beckons for rookie maroon Robert Toia
-
Noosa News22 hours agoDefence investigation finds Taipan pilot’s actions possibly prevented further fatalities in crash
-
General20 hours agoDairy farmers devastated by floods across parts of New South Wales